Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats

Hypertension

Volumn 27, Issue 5, 1996, Pages 1108-1114

  Jyothirmayi, Garikiparthy N ^a   Alluru, Indira ^a   Reddi, Alluru S ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

adrenergic alpha antagonists; albuminuria; antihypertensive therapy; blood pressure; diabetic nephropathy; rats

Indexed keywords

ALBUMIN; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; GLYCOSAMINOGLYCAN; GLYCOSYLATED HEMOGLOBIN; HEPARAN SULFATE; INSULIN ZINC SUSPENSION; PROTEOGLYCAN;

ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPERTENSION; MALE; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029972395     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.5.1108     Document Type: Article

References (57)

1. United States Renal Data System 1991 Annual Data Report. Am J Kidney Dis. 1991;18(suppl 2):1-127.
2. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease: with emphasis on the stage of incipient nephropathy. Diabetes. 1983;32(suppl 2):64-78.
3. Olson JL. Diabetes mellitus. In: Heptinstall RH, ed. Pathology of the Kidney. Boston, Mass: Little. Brown & Co; 1992:1715-1763.
4. Reddi AS, Camerini-Davalos RA. Diabetic nephropathy: an update. Arch Intern Med. 1990;150:31-43.
5. Viberti GC, Jarrett RJ, Mahmud U, Hill RD, Argyropoulos A, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1:1430-1432.
6. Parving H-H, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR. Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh). 1982;100:550-555.
7. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89-93.
8. Mogensen CE. Prediction of clinical diabetic nephropathy in IDDM patients: alternatives to microalbuminuria? Diabetes. 1990; 39:761-767.
9. Abbott KC, Sanders LR, Bakris GL. Microalbuminuria in non-insulin-dependent diabetes mellitus: implications for renal survival. Arch Intent Meet. 1994;154:146-153.
10. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control of late complications of type I diabetes. Lancet. 1993;341:1306-1309.
11. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Trial. Kidney Int. 1995;47:1703-1720.
12. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-268.
13. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest. 1976;36:383-388.
14. Parving H-H, Andersen AR, Smidt UM. Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;2:1175-1179.
15. Viberti GC, Bending JJ. Early diabetic nephropathy: detection and prevention. Adv Nephrol. 1988;17:101-112.
16. Anderson S, Brenner BM. Therapeutic implications of converting-enzyme inhibitors in renal disease. Am J Kidney Dix. 1987;10(suppl 1):81-87.
17. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments of progression on diabotic renal disease. Arch Intern Med. 1993;53:973-980.
18. Lewis EJ, Hunsicker LG, Bain RP, Ronde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
19. Bakris GL. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med. 1993;118: 643-644.
20. Viberti GC, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994; 271:275-279.
21. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995;155:1073-1080.
22. Epstein M. Calcium antagonists and diabetic nephropathy. Arch Intern Med. 1991;151:2361-2364.
23. Bakris GL. Calcium abnormalities and the diabetic, hypertensive patient: Implications for renal preservation. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Philadelphia, Pa: Hanley & Belfus; 1992:367-389.
24. Anderson S, Rennke HG, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int. 1992;41: 891-897.
25. Jyothirmayi GN, Reddi AS. Effect of diltiazem on glomerular beparan sulfate and albuminuria in diabetic rats. Hypertension. 1993;21:795-802.
26. Kanwar YS, Liu ZZ, Kashihara N, Wallner EI. Current status of the structural and functional basis of glomerular filtration and proteinuria. Semin Nephrol. 1991;11:390-413.
27. 125I bovine serum albumin. Lab Invest. 1982;47:177-184.
28. Van Den Born J, Van Den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assmann KJM, Berden JHM. A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int. 1992;41:115-123.
29. Parthasarathy N, Spiro RG. Effect of diabetes on the glycosamino-glycan component of the human glomerular basement membrane. Diabetes. 1982;31:738-741.
30. 35S)sulfate incorporation into glomerular basement membrane glycosaminoglycans is decreased in experimental diabetes. Lab Clin Med. 1981;98:715-722.
31. 35-glucopeptide metabolism by diabetic glomeruli and aorta. Diabetes. 1982;31:418-425.
32. Kanwar YS, Rosenzweig LJ, Linker A, Jakubowski ML. Decreased de novo synthesis of glomerular proteoglycans in diabetes: biochemical and auto-radiographic evidence. Proc Natl Acad Sci U S A. 1983;80:2272-2275.
33. Reddi AS. Glomerular and urinary glycosaminoglycans in diabetic rats. Clin Chim Acta. 1990;189:211-220.
34. Rohrbach DH, Hassell JR, Kleinman HK, Martin GR. Alterations in the basement membrane (heparan sulfate) proteoglycan in diabetic mice. Diabetes. 1982;31:185-188.
35. Reddi AS. Prevention of albuminuria by captopril in diabetic rats. Gen Pharmacol. 1991;22:323-328.
36. Reddi AS, Ramamurthi R, Miller M, Dhuper S, Lasker N. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Meet Metab Biol. 1991;45: 119-131.
37. Brodows RG, Nichols D, Shaker G, Kubasik NP. Evaluation of a new radioimmunoassay for urinary albumin. Diabetes Care. 1986;9: 189-193.
38. Weibel ER, Gomez DM. A principle for counting tissue structures on random sections. J Appl Physiol. 1962;17:343-348.
39. Meyer TW. Mechanisms of proteinuria in diabetic renal disease. Semin Nephrol. 1990;10:194-202.
40. Myers BD, Nelson RG, Tan M, Beck GJ, Bennett PH, Knowler WC, Blouch K, Mitch WE. Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int. 1995;47:1781-1789.
41. Hosteller TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes. Kidney Int. 1981;19:410-415.
42. Zatz R, Brenner BM. Pathogenesis of diabetic microangiopathy: the hemodynamic view. Am J Meet. 1986;80:443-453.
43. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993;43:1210-1218.
44. Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, Narins RG. Intraglomerular pressure and mesangial stretching stimulate extra-cellular matrix formation in the rat. J Clin Invest. 1992;90: 1932-1943.
45. Shaklai N, Garlick RL, Bunn HF. Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J Biol Chem. 1984;259:3812-3817.
46. Ghiggeri GM, Candiano G, Delfino G, Bianchini F, Queirolo C. Glucosyl albumin and diabetic microalbuminuria: demonstration of an altered renal handling. Kidney Int. 1984;25:565-570.
47. Erley CM, Haefele U, Heyne N, Braun N, Risler T. Microalbuminuria in essential hypertension: reduction by different antihypertensive drugs. Hypertension. 1993;21:810-815.
48. Feher MD. Doxazosin therapy in the treatment of diabetic hypertension. Am Heart J. 1991;121:1291-1301.
49. Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. Am Heart J. 1991;121:1307-1311.
50. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care. 1991;14:203-209.
51. Kageyama S, Yamamoto J, Minura A, Sakurai, T, Ishibashi K, Aihara K, Taniguchi I, Ito K, Isogai Y. Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther. 1993;15:829-837.
52. 2+ channel antagonists and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes. 1995;44: 665-671.
53. Huupponen R, Lehtonen A, Vahatalo M. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol. 1992;43:365-368.
54. Maheux P, Facchini F, Jeppesen J, Greenfield MS, Clinkingbeard C, Chen YDI, Reaven GM. Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension: comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus. Am J Hypertens. 1994;7:416-424.
55. Steffes MW, Brown DM, Basgen JM, Mauer SM. Amelioration of mesangial volume and surface alterations following islet transplantation in diabetic rats. Diabetes. 1980;29:509-515.
56. Anderson S, Rennke HG, Garcia DL, Brenner BM, Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int. 1989;36:526-536.
57. Gaber L, Walton C, Brown S, Bakris G. Effects of different anti-hypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994;46; 161-169.